Lobe Sciences Stock Fundamentals
| LOBEF Stock | USD 0 0.0003 20.00% |
Lobe Sciences fundamentals help investors to digest information that contributes to Lobe Sciences' financial success or failures. It also enables traders to predict the movement of Lobe OTC Stock. The fundamental analysis module provides a way to measure Lobe Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lobe Sciences otc stock.
Lobe |
Lobe Sciences OTC Stock Return On Asset Analysis
Lobe Sciences' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Lobe Sciences Return On Asset | -0.65 |
Most of Lobe Sciences' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lobe Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Lobe Sciences has a Return On Asset of -0.6505. This is 92.57% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is notably higher than that of the company.
Lobe Sciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lobe Sciences's current stock value. Our valuation model uses many indicators to compare Lobe Sciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lobe Sciences competition to find correlations between indicators driving Lobe Sciences's intrinsic value. More Info.Lobe Sciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lobe Sciences' earnings, one of the primary drivers of an investment's value.Lobe Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lobe Sciences' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Lobe Sciences could also be used in its relative valuation, which is a method of valuing Lobe Sciences by comparing valuation metrics of similar companies.Lobe Sciences is currently under evaluation in return on asset category among its peers.
Lobe Fundamentals
| Return On Equity | -2.8 | |||
| Return On Asset | -0.65 | |||
| Current Valuation | (6.77 M) | |||
| Shares Outstanding | 76.97 M | |||
| Shares Owned By Insiders | 2.85 % | |||
| Price To Earning | 1.34 X | |||
| Price To Book | 0.76 X | |||
| Price To Sales | 7.72 X | |||
| Gross Profit | 841.56 K | |||
| EBITDA | (4.11 M) | |||
| Net Income | (12.25 M) | |||
| Cash And Equivalents | 1.38 M | |||
| Cash Per Share | 0.04 X | |||
| Current Ratio | 2.23 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (2.73 M) | |||
| Earnings Per Share | (0.31) X | |||
| Beta | 2.64 | |||
| Market Capitalization | 2.01 M | |||
| Total Asset | 1.75 M | |||
| Z Score | -6.6 | |||
| Net Asset | 1.75 M |
About Lobe Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lobe Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lobe Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lobe Sciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Lobe OTC Stock
Lobe Sciences financial ratios help investors to determine whether Lobe OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lobe with respect to the benefits of owning Lobe Sciences security.